ABSTRACT
Background: Peptide receptor radionuclide therapy (PRRT) is a validated treatment for somatostatin receptor overexpressing neuroendocrine tumors (NETs). The NETTER-1 trial demonstrated a pronounced positive effect on progression-free-survival compared to high dose somatostatin analogs (SSAs), with a strong tendency toward overall survival benefit. Our aim was to investigate the influence of pretreatment with everolimus and/or sunitinib on subacute hematotoxicity of PRRT. To assess the influence of prior treatment with everolimus/sunitinib might be of clinical relevance due to the link between short-term hematotoxicity and increased incidence of late hematotoxicity.Material and methods: Our single-center retrospective study enrolled all patients treated with 177Lu-DOTATATE PRRT (1-4 cycles of 7.4 GBq), between November 2013 and July 2018. Patients were assigned to two groups according to their pretreatment: no targeted agents (N = 41), or targeted agents (everolimus, sunitinib or both; N = 41). The end point was subacute hematotoxicity, defined as the nadir value between the first administration until 3 months after the last administration, using the CTCAE 4.03 classification. The impact of splenectomy was also explored.Results: Eighty percent of patients had a primary gastroenteropancreatic NET. No statistically significant differences in severe subacute hematotoxicity were seen in the pretreated group vs. the naive group for hemoglobin (grade 3/4: 12% vs. 22%), neither for leucocytes (grade 3/4: 10% vs. 7%), neutrophils (grade 3/4: 5% vs. 7%), lymphocytes (grade 3/4: 49% vs. 37%) and platelets (grade 3/4: 15% vs. 15%). Furthermore, we observed significantly lower toxicity for total white blood cells, lymphocytes and platelets in the subgroup that had splenectomy (N = 12). Limitations of this study include the potential bias in lack of use of targeted agents in patients more susceptible to toxicity, and the limited number of patients and events.Conclusions: In a patient cohort with NET pretreated with everolimus and/or sunitinib, we could not demonstrate a significant effect of prior/pretreatment with everolimus and/or sunitinib on the subacute hematotoxicity of 177Lu-DOTATATE PRRT.
Subject(s)
Antineoplastic Agents/therapeutic use , Everolimus/therapeutic use , Hematologic Diseases/chemically induced , Intestinal Neoplasms/drug therapy , Neuroendocrine Tumors/drug therapy , Octreotide/analogs & derivatives , Organometallic Compounds/adverse effects , Pancreatic Neoplasms/drug therapy , Radiopharmaceuticals/adverse effects , Somatostatinoma/drug therapy , Stomach Neoplasms/drug therapy , Sunitinib/therapeutic use , Adult , Aged , Aged, 80 and over , Anemia/chemically induced , Female , Humans , Intestinal Neoplasms/blood , Leukopenia/chemically induced , Lymphopenia/chemically induced , Male , Middle Aged , Neuroendocrine Tumors/blood , Octreotide/administration & dosage , Octreotide/adverse effects , Organometallic Compounds/administration & dosage , Organometallic Compounds/pharmacokinetics , Pancreatic Neoplasms/blood , Progression-Free Survival , Radiopharmaceuticals/administration & dosage , Receptors, Somatostatin/metabolism , Retrospective Studies , Somatostatinoma/blood , Somatostatinoma/mortality , Splenectomy , Stomach Neoplasms/blood , Thrombocytopenia/chemically induced , Young AdultABSTRACT
We present the case of a 13-year-old boy with bleeding complications from a Meckel diverticulum (MD), which was scintigraphically confirmed. A first exploratory laparoscopy was unsuccessful in identifying the diverticulum. A new Tc-pertechnetate scintigraphy (including SPECT/CT), 3 years later, suggested the anatomical location and was helpful during the surgical exploration for the MD by radioguided surgery. Radioguidance is helpful in pathologies characterized by small size or variable anatomical location. A MD with ectopic gastric mucosa can be distinguished from the rest of the small bowel based on selective Tc-pertechnetate uptake in the gastric mucosa, with limited background activity.
